U.S. Markets closed

BioSpecifics announces presentation of additional Phase III data

BioSpecifics Technologies announced that additional data will be presented from the Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Auxilium),and known as IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies). These data will be presented at two oral presentations at the Sexual Medicines Society of North America, SMSNA/International Society for Sexual Medicine, ISSM, Joint Annual Meeting on August 27 and 29, 2012 in Chicago, IL.